Management of Decompensated Liver Cirrhosis

Introduction to Decompensated Liver Cirrhosis Management

The American Association for the Study of Liver Diseases recommends that the management of decompensated liver cirrhosis requires immediate initiation of etiological treatment combined with aggressive management of specific complications, as treating the underlying cause is directly associated with decreased risk of further decompensation and increased survival 1

The European Association for the Study of the Liver suggests that alcoholic cirrhosis treatment should mandate complete and permanent alcohol cessation, which can lead to "re-compensation" and excellent long-term outcomes in some patients, though progression may continue in others despite abstinence 1
The American Association for the Study of Liver Diseases recommends that hepatitis B treatment should initiate antiviral therapy immediately regardless of HBV DNA level using entecavir or tenofovir as first-line agents due to their potent antiviral efficacy and high genetic barrier to resistance 1
The European Association for the Study of the Liver suggests that hepatitis C treatment should start direct-acting antivirals immediately, as this improves liver function, reduces portal hypertension, and likely improves outcome 2, 1
The American Association for the Study of Liver Diseases recommends that autoimmune hepatitis treatment should use immunosuppressive therapy, which shows clear beneficial effects 2

The European Association for the Study of the Liver recommends that ascites management should consist of sodium restriction to less than 5 g/day plus spironolactone 50-100 mg/day (maximum 400 mg/day) with or without furosemide 20-40 mg/day (maximum 160 mg/day) 1, 4
The American Association for the Study of Liver Diseases suggests that variceal bleeding treatment should initiate vasoactive drugs immediately upon suspicion of variceal bleeding, even before endoscopic confirmation 1, 4
The European Association for the Study of the Liver recommends that hepatic encephalopathy treatment should use lactulose or lactitol as first-line therapy, as it reduces mortality and prevents recurrent overt hepatic encephalopathy 5, 4
The American Association for the Study of Liver Diseases suggests that spontaneous bacterial peritonitis (SBP) diagnosis should perform diagnostic paracentesis without delay in all patients with ascites 5
The European Association for the Study of the Liver recommends that renal dysfunction management should avoid nephrotoxic drugs (NSAIDs, aminoglycosides), large volume paracentesis without albumin replacement, and hypotensive medications 5

The American Association for the Study of Liver Diseases recommends that non-selective beta-blockers should be used to decrease risk of ascites, hepatorenal syndrome, SBP, and hepatic encephalopathy beyond variceal bleeding prevention 1, 4
The European Association for the Study of the Liver suggests that anticoagulation with enoxaparin may delay hepatic decompensation and improve survival in patients with Child-Pugh scores 7-10 1, 4

The American Association for the Study of Liver Diseases recommends that rapid nutritional screening should be performed in all patients, assuming high risk for malnutrition if BMI <18.5 kg/m² or Child-Pugh C 1
The European Association for the Study of the Liver suggests that sodium restriction should not be so excessive that it worsens malnutrition 4

The American Association for the Study of Liver Diseases recommends that insulin therapy is the only evidence-based option for treating type 2 diabetes in decompensated cirrhosis 1

The European Association for the Study of the Liver recommends that early referral for liver transplantation evaluation is essential for appropriate candidates, as decompensation significantly worsens prognosis 1, 4
The American Association for the Study of Liver Diseases suggests that mean pulmonary arterial pressure ≥45 mmHg is an absolute contraindication to liver transplantation 1

The American Association for the Study of Liver Diseases recommends that telemedicine and remote monitoring technologies should be used to enable early detection of complications and reduce hospital readmissions 1, 4
The European Association for the Study of the Liver suggests that heart rate variability monitoring may identify patients at risk of decompensation; loss of HRV is associated with decompensation and inflammation 6, 1